Source: Eur Respir J 2010; 36: 1080-1087
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Almirall J., Bolíbar I., Serra-Prat M., Palomera E., Roig J., Hospital I., Carandell E., Agustí M., Ayuso P., Estela A., Torres A.. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010; 36: 1080-1087

Member's Comments

No comment yet.

Related content which might interest you: Inhaled drugs as risk factors for community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Treatment failure of community-acquired pneumonia: risk factors and consequences Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Community-acquired pneumonia: severity and antibiotic treatments Source: ERS Course 2018 - Respiratory Infections Year: 2018 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Risk factors of paediatric community-acquired pneumonia Source: Eur Respir J 2011; 37: 724-725 Year: 2011 Risk factors of community-acquired pneumonia in children Source: Eur Respir J 2010; 36: 1221-1222 Year: 2010 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Risk factors for pulmonary tuberculosis in community-acquired pneumonia Source: Eur Respir J 2014; 43: 1214 Year: 2014 Risk factors for pulmonary tuberculosis in community-acquired pneumonia Source: Eur Respir J 2014; 43: 1213 Year: 2014 The main risk factors of the community-acquired pneumonia delayed course Source: Eur Respir J 2005; 26: Suppl. 49, 643s Year: 2005 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004